Precision’s Deb Phippard, PhD, and Jared Kohler, PhD, address the potential of Big Data, analytics, and technology to increase efficiency and decrease costs in the drug development process in a guest column for Bioprocess Online. Read the full article here:

Precision’s Tomas Philipson’s latest Forbes.com Op-Ed examines California’s recently enacted vaccination mandate, and the application of economic epidemiology.

Precision’s Dana Goldman and Senior Research Economist Karen Van Nuys, along with co-authors Victor J Dzau, Geoffrey S Ginsburg and David Agus, address new developments in personalized medicine.

Precision’s Tomas Philipson in his regular column in Forbes.com, talks about the precision medicine initiative as a more useful approach towards appropriate adherence behavior.

In Health Affairs, PHE’s Goldman and Lakdawalla suggest it’s time for value-based payment in oncology.